Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12597) 12597
Book Chapter (49) 49
Dissertation (20) 20
Publication (14) 14
Book / eBook (12) 12
Magazine Article (7) 7
Newspaper Article (7) 7
Conference Proceeding (5) 5
Web Resource (4) 4
Government Document (2) 2
Newsletter (2) 2
Trade Publication Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (10402) 10402
life sciences & biomedicine (9294) 9294
humans (7665) 7665
animals (5276) 5276
poly polymerases - metabolism (5035) 5035
apoptosis (4543) 4543
poly polymerase (3361) 3361
oncology (3332) 3332
apoptosis - drug effects (2803) 2803
mice (2597) 2597
poly polymerase inhibitors (2524) 2524
cell line, tumor (2514) 2514
biochemistry & molecular biology (2456) 2456
biological and medical sciences (2361) 2361
female (2356) 2356
cancer (2287) 2287
cell biology (2238) 2238
proteins (2130) 2130
male (1955) 1955
dna damage (1924) 1924
ribose (1838) 1838
dna repair (1704) 1704
medical sciences (1656) 1656
tumors (1545) 1545
deoxyribonucleic acid--dna (1506) 1506
poly polymerase-1 (1459) 1459
enzyme inhibitors - pharmacology (1318) 1318
rats (1310) 1310
cell death (1275) 1275
pharmacology & pharmacy (1267) 1267
cell cycle (1215) 1215
caspase (1203) 1203
breast cancer (1200) 1200
gene expression (1200) 1200
antineoplastic agents - pharmacology (1196) 1196
caspases - metabolism (1194) 1194
signal transduction (1153) 1153
kinases (1126) 1126
mutation (1126) 1126
chemotherapy (1121) 1121
cell survival - drug effects (1103) 1103
poly polymerases - genetics (1092) 1092
science & technology - other topics (1082) 1082
research (1067) 1067
cell line (1066) 1066
multidisciplinary sciences (1063) 1063
caspase-3 (1052) 1052
research article (1038) 1038
adenosine diphosphate (982) 982
cell proliferation - drug effects (980) 980
analysis (978) 978
cells, cultured (948) 948
caspase 3 - metabolism (940) 940
phosphorylation (922) 922
poly polymerase 1 (879) 879
medicine (876) 876
dose-response relationship, drug (871) 871
blotting, western (867) 867
fundamental and applied biological sciences. psychology (837) 837
oxidative stress (837) 837
cancer therapies (826) 826
monosaccharides (816) 816
enzymes (813) 813
sugars (812) 812
flow cytometry (801) 801
cytotoxicity (799) 799
cell proliferation (783) 783
health aspects (782) 782
mitochondria (782) 782
genetic aspects (771) 771
science (753) 753
dna (750) 750
pharmacology. drug treatments (722) 722
biology (719) 719
benzamides - pharmacology (705) 705
ovarian cancer (697) 697
signal transduction - drug effects (693) 693
care and treatment (687) 687
tumor cells, cultured (653) 653
caspase 3 (647) 647
reactive oxygen species - metabolism (639) 639
enzyme activation (638) 638
rodents (621) 621
parp (617) 617
antineoplastic agents (610) 610
poly polymerase inhibitors - pharmacology (604) 604
poly (594) 594
time factors (587) 587
neurosciences (583) 583
cell survival (581) 581
biochemistry (580) 580
neurosciences & neurology (563) 563
medicine, research & experimental (561) 561
proto-oncogene proteins c-bcl-2 - metabolism (561) 561
research & experimental medicine (561) 561
enzyme activation - drug effects (551) 551
physiological aspects (547) 547
mitochondria - metabolism (544) 544
apoptosis - physiology (539) 539
inhibitors (532) 532
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12629) 12629
Japanese (70) 70
Chinese (60) 60
French (36) 36
Russian (19) 19
German (17) 17
Portuguese (10) 10
Polish (8) 8
Korean (6) 6
Hungarian (5) 5
Norwegian (5) 5
Ukrainian (4) 4
Spanish (2) 2
Czech (1) 1
Hebrew (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety & clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with Poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A dose-escalation, phase I study
by Lee, Jung-Min and Cimino-Mathews, Ashley and Peer, Cody J and Zimmer, Alexandra and Lipkowitz, Stanley and Annunziata, Christina M and Cao, Liang and Harrell, Maria I and Swisher, Elizabeth M and Houston, Nicole and Botesteanu, Dana-Adriana and Taube, Janis M and Thompson, Elizabeth and Ogurtsova, Aleksandra and Xu, Haiying and Nguyen, Jeffers and Ho, Tony W and Figg, William D and Kohn, Elise C
Journal of clinical oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
by Tutt, Andrew, Dr and Robson, Mark, MD and Garber, Judy E, MD and Domchek, Susan M, MD and Audeh, M William, MD and Weitzel, Jeffrey N, Prof and Friedlander, Michael, Prof and Arun, Banu, Prof and Loman, Niklas, MD and Schmutzler, Rita K, Prof and Wardley, Andrew, MD and Mitchell, Gillian, MD and Earl, Helena, PhD and Wickens, Mark, BSc and Carmichael, James, Prof
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 235 - 244
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | General aspects | Medical sciences | Tumors | Prospective Studies | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Maximum Tolerated Dose | Phthalazines - therapeutic use | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Aged | Genes, BRCA1 | Antimitotic agents | Dosage and administration | Antineoplastic agents | Drug therapy | Testing | Ovarian cancer | Medical research | Breast cancer | Mutation | Index Medicus | Abridged Index Medicus | Anemia | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
by Audeh, M William, Dr and Carmichael, James, Prof and Penson, Richard T, MD and Friedlander, Michael, Prof and Powell, Bethan, Prof and Bell-McGuinn, Katherine M, PhD and Scott, Clare, MD and Weitzel, Jeffrey N, Prof and Oaknin, Ana, MD and Loman, Niklas, MD and Lu, Karen, Prof and Schmutzler, Rita K, Prof and Matulonis, Ursula, MD and Wickens, Mark, BSc and Tutt, Andrew, PhD
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 245 - 251
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | General aspects | Medical sciences | Female genital diseases | Tumors | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - genetics | Maximum Tolerated Dose | Phthalazines - therapeutic use | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Aged | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Antimitotic agents | Dosage and administration | Antineoplastic agents | Drug therapy | Testing | Ovarian cancer | Chemotherapy | Breast cancer | Mutation | Cancer therapies | Index Medicus | Abridged Index Medicus | Anemia | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials
by Wang, Lei and Yang, Changyong and Xie, Chengying and Jiang, Jiahua and Gao, Mingzhao and Fu, Li and Li, Yun and Bao, Xubin and Fu, Haoyu and Lou, Liguang
Cancer science, ISSN 1347-9032, 03/2019, Volume 110, Issue 3, pp. 1064 - 1075
toxicity | pharmacokinetics | poly(ADP‐ribose) polymerase | fluzoparib | antitumor activity | poly(ADP-ribose) polymerase | Life Sciences & Biomedicine | Oncology | Science & Technology | DNA Repair - drug effects | Apoptosis - drug effects | Humans | Rats | Clinical Trials as Topic | Xenograft Model Antitumor Assays - methods | Piperazines - pharmacology | Rats, Sprague-Dawley | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Poly(ADP-ribose) Polymerases - metabolism | Animals | DNA Breaks, Double-Stranded - drug effects | Mice, Nude | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Clinical trials | DNA damage | Sugars | Monosaccharides | Cell proliferation | Homologous recombination | Cytotoxicity | Metastasis | Kinases | Cancer therapies | DNA repair | Stomach cancer | Defects | Ovarian cancer | Homologous recombination repair | Enzymatic activity | Ribose | Paclitaxel | Xenografts | Drug dosages | Deoxyribonucleic acid--DNA | Enzymes | Poly(ADP-ribose) polymerase | Breast cancer | FDA approval | Poly(ADP-ribose) Polymerase 1 | Antitumor activity | Hypoxia | Software | Apoptosis | Pharmaceuticals | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
by Matulonis, U.A and Wulf, G.M and Barry, W.T and Birrer, M and Westin, S.N and Farooq, S and Bell-McGuinn, K.M and Obermayer, E and Whalen, C and Spagnoletti, T and Luo, W and Liu, H and Hok, R.C and Aghajanian, C and Solit, D.B and Mills, G.B and Taylor, B.S and Won, H and Berger, M.F and Palakurthi, S and Liu, J and Cantley, L.C and Winer, E
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 512 - 518
Breast cancer | Olaparib | PARP-inhibitors | BKM120 | Ovarian cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Phosphoinositide-3 Kinase Inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasm Grading | Germ-Line Mutation | Adult | Female | Piperazines - pharmacokinetics | Ovarian Neoplasms - drug therapy | Aminopyridines - administration & dosage | Phthalazines - administration & dosage | Morpholines - administration & dosage | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | BRCA1 Protein - genetics | Breast Neoplasms - genetics | Poly(ADP-ribose) Polymerases - genetics | Breast Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Aged | Morpholines - pharmacokinetics | BRCA2 Protein - genetics | Index Medicus | ovarian cancer | Editor's Choice | olaparib | breast cancer | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development
by Scott, Clare L and Swisher, Elizabeth M and Kaufmann, Scott H
Journal of clinical oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 12, pp. 1397 - 1406
Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms, Glandular and Epithelial - enzymology | Clinical Trials, Phase III as Topic | Animals | Humans | Enzyme Inhibitors - pharmacology | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Enzyme Inhibitors - therapeutic use | Ovarian Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Index Medicus | Bon | Biology of Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text PARP inhibitors: Synthetic lethality in the clinic
by Lord, Christopher J and Ashworth, Alan
Science (American Association for the Advancement of Science), ISSN 0036-8075, 03/2017, Volume 355, Issue 6330, pp. 1152 - 1158
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Poly(ADP-ribose) Polymerase Inhibitors - chemistry | Humans | Antineoplastic Protocols | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Synthetic Lethal Mutations | DNA Repair - genetics | Antineoplastic Agents - chemistry | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | DNA Damage - genetics | Germ-Line Mutation | Antineoplastic Agents - pharmacology | Ubiquitin-Protein Ligases - genetics | BRCA2 Protein - genetics | Complications and side effects | Chemical inhibitors | Care and treatment | Methods | Cancer | Drugs | BRCA2 protein | BRCA1 protein | DNA polymerase | Poly(ADP-ribose) | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Lethality | DNA repair | Inhibitors | Ribose | Genetics | Mutation | Repair | Deoxyribonucleic acid--DNA | Tumors | Index Medicus | Therapy | Defects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
by Sandhu, Shahneen K, MD and Schelman, William R, MD and Wilding, George, MD and Moreno, Victor, MD and Baird, Richard D, PhD and Miranda, Susana, BSc and Hylands, Lucy, BSc and Riisnaes, Ruth, FIBMS and Forster, Martin, PhD and Omlin, Aurelius, MD and Kreischer, Nathan, MSc and Thway, Khin, MD and Gevensleben, Heidrun, MD and Sun, Linda, PhD and Loughney, John, PhD and Chatterjee, Manash, PhD and Toniatti, Carlo, PhD and Carpenter, Christopher L, MD and Iannone, Robert, MD and Kaye, Stan B, Prof and de Bono, Johann S, Prof and Wenham, Robert M
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 882 - 892
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Male | Ovarian Neoplasms - genetics | Tissue Distribution | Prostatic Neoplasms - genetics | Neoplasms - genetics | Adult | Female | Piperidines - pharmacokinetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Neoplasm Recurrence, Local - diagnosis | Mutation - genetics | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | BRCA1 Protein - genetics | Maximum Tolerated Dose | Indazoles - pharmacokinetics | Piperidines - therapeutic use | Heterozygote | Neoplasm Recurrence, Local - genetics | Aged | Neoplasms - pathology | BRCA2 Protein - genetics | Indazoles - therapeutic use | Cohort Studies | Cancer patients | Analysis | Genetic aspects | Genetic transcription | Sugars | Cancer | Monosaccharides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights